Biological systems involved in disease are inherently complex and targeting a single receptor/ligand interaction or an individual pathway employing monotherapy often does not mediate maximal therapeutic benefit. Cancer immunotherapy results have shown that a combination of two separate antibodies can produce improved clinical outcomes as compared to monotherapy. There is a pressing medical need to develop technology that enables interdiction of multiple pathways by efficiently producing a single drug product that contains more that one therapeutic antibody.

The MabPair™ Platform
Our proprietary MabPair™ platform enables the development of custom-designed antibody combinations that provide the synergy of a two full-antibody combination thus reducing the opportunity for tumor escape and drug resistance. It also offers the advantages regarding convenience of administration and reduced cost when compared to conventional antibody combination therapies.

Bispecific Platform
Our proprietary bispecific technology platform enables the formation of stable heterodimeric bispecific antibodies that can be expressed and purified using standard antibody production methodology. This bispecific platform is used to generate novel therapeutic antibody candidates.

Sound Biologics consists of a team of energetic, experienced scientists possessing a combined experience of >100 years in the functional areas of antibody engineering, cancer biology, immunology, bioreactor, cell line development, purification process development and analytics. The team’s record of innovation can be found in the numerous issued patents to company scientists, and in their leadership or programs/teams that developed multiple novel biotherapies from discovery to clinical testing.